The risk model established based on the above five critical genes—CTSE, MAP1A, FXYD6, XAGE2, and CASQ2—classifies BLCA patients into high- and low-risk groups, revealing significant differences in various aspects of clinicopathologic features, prognosis, and treatment outcomes. This evidence concerns the gene MAP1A and bladder transitional cell carcinoma.